Found: 22
Select item for more details and to access through your institution.
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 745, doi. 10.1007/s40121-024-00944-z
- By:
- Publication type:
- Article
A Response to: Letter to the Editor Regarding 'Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age'.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 1, p. 295, doi. 10.1007/s40121-022-00719-4
- By:
- Publication type:
- Article
Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 2701, doi. 10.1007/s40121-021-00544-1
- By:
- Publication type:
- Article
Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 3, p. 1765, doi. 10.1007/s40121-021-00485-9
- By:
- Publication type:
- Article
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis.
- Published in:
- Infectious Diseases & Therapy, 2020, v. 9, n. 2, p. 341, doi. 10.1007/s40121-020-00294-6
- By:
- Publication type:
- Article
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
- Published in:
- Infectious Diseases & Therapy, 2020, v. 9, n. 2, p. 305, doi. 10.1007/s40121-020-00287-5
- By:
- Publication type:
- Article
Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria.
- Published in:
- Infectious Diseases & Therapy, 2019, v. 8, n. 1, p. 63, doi. 10.1007/s40121-018-0226-x
- By:
- Publication type:
- Article
Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium.
- Published in:
- Infectious Diseases & Therapy, 2019, v. 8, n. 1, p. 1, doi. 10.1007/s40121-018-0222-1
- By:
- Publication type:
- Article
Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
- Published in:
- Infectious Diseases & Therapy, 2018, v. 7, n. 3, p. 353, doi. 10.1007/s40121-018-0206-1
- By:
- Publication type:
- Article
Comment on: 'Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children'.
- Published in:
- Infectious Diseases & Therapy, 2015, v. 4, n. 2, p. 227, doi. 10.1007/s40121-015-0063-0
- By:
- Publication type:
- Article
Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
- Published in:
- BMC Infectious Diseases, 2012, v. 12, n. 1, p. 101, doi. 10.1186/1471-2334-12-101
- By:
- Publication type:
- Article
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
- Published in:
- BMC Infectious Diseases, 2012, v. 12, n. 1, p. 175, doi. 10.1186/1471-2334-12-175
- By:
- Publication type:
- Article
Economic evaluation of meningococcal vaccines: considerations for the future.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 11, p. 1025, doi. 10.2165/11535540-000000000-00000
- By:
- Publication type:
- Article
Risk of Pneumococcal Disease in Children With Chronic Medical Conditions in the Era of Pneumococcal Conjugate Vaccine.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 5, p. 615, doi. 10.1093/cid/ciu348
- By:
- Publication type:
- Article
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
- Published in:
- PLoS ONE, 2018, v. 13, n. 7, p. 1, doi. 10.1371/journal.pone.0201245
- By:
- Publication type:
- Article
Rates of pneumonia among children and adults with chronic medical conditions in Germany.
- Published in:
- 2015
- By:
- Publication type:
- journal article